We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+5.7%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$379M
AUM Growth
+$697K
Cap. Flow
-$7.42M
Cap. Flow %
-1.96%
Top 10 Hldgs %
54.1%
Holding
70
New
14
Increased
14
Reduced
8
Closed
4

Top Buys

Rank Stock Value
1
SUPN icon
Supernus Pharmaceuticals
SUPN
+$6.21M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$5.89M
3
HRMY icon
Harmony Biosciences
HRMY
+$4.98M
4
INCY icon
Incyte
INCY
+$4.91M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$4.17M

Top Sells

Rank Stock Value
1
EXEL icon
Exelixis
EXEL
+$18.3M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$14.3M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$8.11M
4
ILMN icon
Illumina
ILMN
+$6.26M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$5.95M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HALO icon
26
Halozyme
HALO
$12.1B
$3.75M 0.99%
82,633
+48,000
+139% +$2.12M
DCPH
27
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$3.66M 0.97%
100,000
– –
JAZZ icon
28
Jazz Pharmaceuticals
JAZZ
$16.3B
$3.55M 0.94%
+20,000
New +$3.46M
ITCI
29
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$3.24M 0.86%
79,456
– –
INSM icon
30
Insmed
INSM
$26.5B
$2.85M 0.75%
100,100
+66,500
+198% +$1.97M
DYN icon
31
Dyne Therapeutics
DYN
$4.87B
$2.84M 0.75%
135,000
+41,114
+44% +$773K
MRTX
32
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$2.73M 0.72%
16,900
-50,500
-75% -$8.11M
HCM icon
33
HUTCHMED
HCM
$2.16B
$2.67M 0.71%
+68,000
New +$1.96M
STRO icon
34
Sutro Biopharma
STRO
$353M
$2.59M 0.68%
13,933
– –
SRPT icon
35
Sarepta Therapeutics
SRPT
$2.28B
$2.45M 0.65%
31,500
– –
KDNY
36
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$2.41M 0.64%
+170,821
New +$2.73M
ZLAB icon
37
Zai Lab
ZLAB
$3.01B
$2.26M 0.6%
+12,800
New +$2.06M
NKTX icon
38
Nkarta
NKTX
$197M
$2.21M 0.58%
+70,000
New +$2.02M
GH icon
39
Guardant Health
GH
$22.6B
$2.11M 0.56%
+17,000
New +$2.29M
EXEL icon
40
Exelixis
EXEL
$13.7B
$1.85M 0.49%
101,534
-785,000
-89% -$18.3M
ASND icon
41
Ascendis Pharma A/S
ASND
$16.4B
$1.81M 0.48%
13,800
– –
BPMC
42
DELISTED
Blueprint Medicines
BPMC
$1.72M 0.45%
19,500
– –
IOVA icon
43
Iovance Biotherapeutics
IOVA
$3.74B
$1.51M 0.4%
58,000
– –
ENTA icon
44
Enanta Pharmaceuticals
ENTA
$402M
$1.5M 0.4%
+34,047
New +$1.67M
APLS
45
DELISTED
Apellis Pharmaceuticals
APLS
$1.48M 0.39%
23,400
– –
ARNA
46
DELISTED
Arena Pharmaceuticals Inc
ARNA
$1.43M 0.38%
21,000
– –
ALLK
47
DELISTED
Allakos
ALLK
$1.34M 0.35%
15,700
– –
EXAS
48
DELISTED
Exact Sciences
EXAS
$1.33M 0.35%
10,700
– –
AGIO icon
49
Agios Pharmaceuticals
AGIO
$2.05B
$1.19M 0.31%
21,500
– –
NKTR icon
50
Nektar Therapeutics
NKTR
$2.55B
$1.15M 0.3%
4,467
– –
1
2
3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q2 2021 Portfolio in Review

As of Q2 2021, International Biotechnology Trust held 70 positions worth $379M, up 0.18% from $378M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

International Biotechnology Trust's Q2 2021 filing shows 14 new, 14 increased, 8 reduced and 4 closed positions. Its largest new stake was Supernus Pharmaceuticals: 202,436 shares worth $6.23M. The largest sale was Exelixis, an estimated $18.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • International Biotechnology Trust's largest Q2 2021 buy was Supernus Pharmaceuticals: 202,436 shares worth $6.23M.
  • International Biotechnology Trust added most to Alnylam Pharmaceuticals in Q2 2021, an estimated $5.89M increase.
  • International Biotechnology Trust's biggest Q2 2021 reduction was Exelixis, cutting an estimated $18.3M.
  • International Biotechnology Trust fully exited Illumina in Q2 2021, selling an estimated $6.26M.
  • International Biotechnology Trust's ten largest holdings make up 54% of its $379M portfolio in Q2 2021.
  • International Biotechnology Trust opened 14 new positions and closed 4 in Q2 2021.
  • International Biotechnology Trust's portfolio value rose 0.18% quarter-over-quarter to $379M.

Based on International Biotechnology Trust's 13F filing for Q2 2021, filed 11 Aug 2021.